Treatment Options in Metastatic Castration-Sensitive Prostate Cancer

Dr. Atish Choudhury provides an overview of advances and changes in management of patients with metastatic castration sensitive prostate cancer (mCSPC) in the last decade.

Dr. Choudhury discusses treatment considerations and treatment options for mCSPC.

Dr. Liaw shares the role disease burden and other factors play in treatment selection.

A prostate cancer expert shares long-term data with androgen receptor pathway inhibitors in mCSPC.

Dr. Atish Choudhury discusses safety features to keep in mind when choosing androgen receptor pathway inhibitors.

Dr Bobby Liaw talks about relationship between treatment duration, dosing and efficacy.

Dr Liaw discusses ways to measure response to treatment and what recent data regarding PSA kinetics has shown.

A prostate cancer expert shares rationale for his preferences and choices while sequencing therapies in prostate cancer.

Dr. Bobby Liaw discusses importance of setting expectations regarding common side effects and challenges patients might experiences with treatment.

A prostate cancer expert reemphasizes importance of open communication between patients and healthcare providers.

Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.

Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.